Product Details
| Product Name:
GSK3532795 |
CAS No.:
1392312-45-6 |
| Supply Ability:
10g |
Release date:
2025/07/22 |
Product Introduction
Bioactivity
| Name | GSK3532795 |
| Description | GSK3532795 is a potent, orally active, second-generation HIV-1 maturation inhibitor (EC50s: 10.2, 1.9, 2.7, and 13 nM for HIV-1 WT(human serum), HIV-1 WT, HIV-1 V370A, and HIV-1 ΔV370). |
| In vitro | GSK3532795 demonstrates binding affinities, expressed as equilibrium dissociation constants (Kds), of 3.2 ± 0.6 nM for HIV wild-type (WT), 4.3 ± 2.0 nM for the HIV V362I variant, 6.5 ± 2.2 nM for the HIV V370A variant, and 33.6 ± 5.9 nM for the HIV ΔV370 variant, indicating its effectiveness in targeting different forms of HIV. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | HIV-1 ΔV370 | HIV-1 WT | HIV-1 V370A | GSK-3532795 | GSK3532795 | GSK 3532795 | BMS955176 | BMS 955176 |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
-
CAS:1445830-50-1
$3310.00 / 100mg
-
CAS:1047981-31-6
$1520.00 / 25mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1970.00/25mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-08-21 |
United States